Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating income | -$62.4M | -$143M | -$170M |
| Net income | -$60.4M | -$127M | -$161M |
| EPS (diluted) | -$89.61 | -$3.33 | -$3.64 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$52.4M | -$114M | -$154M |
| Capital expenditures | $621K | $2.21M | $5.00K |
| Free cash flow | -$53.0M | -$116M | -$154M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $34.6M | $96.6M | $124M |
| Total assets | $75.2M | $305M | $294M |
| Total liabilities | $26.0M | $38.1M | $61.5M |
| Shareholders' equity | -$13.1M | $267M | $232M |
| Retained earnings | -$136M | -$264M | -$425M |
| Shares (wtd avg diluted) | 674K | 38.3M | 44.3M |
Every figure is extracted from Kyverna Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.